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Cancer Cell
PreviewsWeischenfeldt et al. (2013) study extends
a growing paradigm regarding the links
between complex rearrangements and
prostate carcinogenesis, while also con-
sidering the age dimension as a possible
player in the spectrum of clinical features
that contribute to disease biology.
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Normal and neoplastic tissues display cellular hierarchies that integrate extracellular cues to maintain tissue
function through bidirectional signals mediated via cell surface proteins. Two papers in Cancer Cell, one in
this issue (Day and colleagues) and one in a recent issue (Binda and colleagues), describe how Eph receptor
tyrosine kinases critically define and regulate the growth of cancer stem cells.Tumors display cellular heterogeneity
through the integration of multiple sup-
portive cell types—vasculature, stroma,
and immune components—as well as
diversity within the neoplastic compart-
ment derived from genetic and epigenetic
variability. Cancers co-opt transcriptional
programs normally active in development
and wound responses, processes in
which stem and progenitor cells con-
tribute, so it is not surprising that cancers
display characteristics of stem and
progenitor cells.
Recent data from human and murine
models support the presence of cellularhierarchies in some advanced cancers
with cancer stem cells (CSC) at the apex
(Chen et al., 2012; Singh et al., 2004).
The CSC field currently lacks a coherent
set of criteria to define these cells. Many
reports mistakenly hold that CSCs simply
represent cells that form spheres in
culture and tumors upon transplantation
(i.e., tumor initiating cells). Rather, CSCs
also mimic normal stem cells to create
a dysfunctional cellular hierarchy with
non-tumorigenic cells derived from the
self-renewing CSC. To fulfill this feature,
the CSC hypothesis needs to employ
strategies to prospectively segregatetumorigenic and non-tumorigenic cells
or perform functional lineage tracing
studies. A critical aspect of these studies
is the requirement to identify and separate
discrete populations and perform func-
tional analyses. In response, researchers
have defined a number of surface mole-
cules that are preferentially expressed
by CSCs and can be interrogated in live
cells. At first blush, the increasing number
of these markers may engender skepti-
cism as to the validity of the CSC hypoth-
esis, but this viewpoint is derived from our
desire to impose simplicity on an inher-
ently complex and dynamic system. First,February 11, 2013 ª2013 Elsevier Inc. 135
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Figure 1. Intrinsic and Extrinsic Regulation of Cancer Stem Cells
(A) Schematic depicting canonical stem cell maintenance pathways shared by many normal and
neoplastic stem cell systems (including Notch, Hedgehog [Hh], Wnt, and intracellular PI3 kinase signaling).
(B) Numerous microenvironmental stimulated pathways also contribute to stem cell maintenance
(including Ephs, EGFRs, PDGFRs, IGFs, VEGFRs, TGFbRs, ILRs, and intracellular STAT signaling).
(C) Many of these extracellular receptors can also be used to enrich for stem cells (including Ephs, CD133,
EGFR, L1CAM, CD44, A2B5, and integrin a6).
(D) Taken together, these factors contribute to the establishment of core stem cell maintenance
pathways consisting of receptor tyrosine kinases (RTKs), transcription factors, epigenetic regulators,
and cell adhesion.
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Previewsmost cancer diagnoses are based on
a presumed cell of origin and pathologic
features, yet no two tumors have an iden-
tical historical development, as demon-
strated by the rapid definition of intrinsic
molecular subtypes in many cancers.
These molecular subtypes likely have
differences in their CSCs, thereby limiting
the universal information of a single bio-
marker. Second, CSCs are not a static or
unitary population but rather have an
evolving identity during the course of the
disease driven in part by the acquisition
of additional genetic lesions. Theplasticity
of cancer is the causative feature for why
cancers of many types are so deadly.
Against this background of our inability
to model the complexity of human
cancers, it might seem hopeless to find
utility in the study of CSCs and the cellular
hierarchy. However, there are rapidly
developing themes that inform possible
points of fragility within cancers that may
be amenable to therapeutic targeting.
Whereas tissue specific stem cells have
been defined as single cells with autono-
mous programs permitting self-renewal,
sustained proliferation, and differentiation
potential, this reductionist view fails to
recognize that stem cells constantly
sense and respond to their environment
with the capacity to modify the environ-
ment either directly or through the activity
of differentiated daughter cells. Therefore,136 Cancer Cell 23, February 11, 2013 ª2013it would be ideal for CSCs to activate
molecular mechanisms that permit
responses to stressful environments and
facilitate bidirectional communication
with the tumor microenvironment (Fig-
ure 1). Cells sense their microenvironment
by detecting other cells through cell
adhesion molecules, extracellular matrix
through integins, and secreted factors
through growth factor receptors. Notably,
members of the receptor tyrosine kinase
(RTK) family have important roles in the
maintenance of the stem cell phenotype.
Modulating levels of RTKs in CSCs can
alter a variety of key CSC phenotypes,
including the self-renewal required to
maintain an undifferentiated state, tumor-
igenicty, and invasiveness as well as
impact overall viability.
In a previous issue and in this issue of
Cancer Cell, Binda et al. (2012) and Day
et al. (2013) explore growth factor recep-
tors that empower bidirectional communi-
cation between cells and the environment
in CSC biology by defining a novel role for
the Eph receptors, namely EphA2 and
EphA3, respectively, in maintenance of
the stem cell phenotype in glioblastoma
(GBM), the most prevalent primary brain
tumor. The Eph RTK subfamily has well-
established roles in cancer as well as
normal stem cell biology, but these
studies are the first to bridge these two
fields for Eph receptors. Interaction of anElsevier Inc.Eph receptor with its cell surface-associ-
ated ephrin ligand elicits bidirectional
signaling between neighboring cells,
although EphA2 can be activated by
soluble ephrin as well (Wykosky et al.,
2008). Eph signaling can influence a host
of cellular processes, including migration,
proliferation, and differentiation. Interest-
ingly, depletion of EphA2 or EphA3 via
ligand engagement or genetically through
RNA interference drives CSCs to differen-
tiate. Attenuation of EphA2 leads to astro-
glial differentiation, whereas depletion of
EphA3 induces both astroglial and
neuronal lineages. These findings provide
support for differentiation-based thera-
pies to target CSCs, with bone morpho-
genic proteins (BMP), members of the
transforming growth factor-b (TGF-b)
superfamily, representing the most devel-
oped driver of differentiation to date (Pic-
cirillo et al., 2006).
Both groups demonstrate an increased
tumor initiating capacity for those cells
with the highest level of EphA2 or EphA3
expression supporting this population as
the putative CSCs within the tumor bulk.
Furthermore, cells expressing EphA3
reside near tumor vasculature, a defined
niche for CSCs (Calabrese et al., 2007).
This finding brings to question if an Eph-
ephrin gradient might exist between
CSCs and the neoplastic non-CSCs akin
to that described for some adult stem
cell niches between the stem and differ-
entiated cells (Genander and Frise´n,
2010). In the case of GBM, the perivascu-
lar niche may support CSCs by being
devoid of the ligand, whereas differentia-
tion could be driven by increased ephrin
expression on cells further from the niche.
This paradigm might not hold true with
EphA2, however, as ephrin-independent
oncogenic activation was shown for this
receptor (Miao et al., 2009). Further explo-
ration of the full cellular hierarchywill aid in
the elucidation of the role of Eph-ephrin
signaling between the CSC and non-
CSC populations.
The mechanism of Eph receptors in
preventing differentiation of CSCs
appears to lie in limiting MAPK signaling
as both groups demonstrate an increase
in ERK phosphorylation upon attenuation
of EphA2 or EphA3. What drives higher
expression of Ephs in CSCs and whether
or not there is niche contribution versus
a cell autonomous stem cell mainte-
nance program is yet to be determined.
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PreviewsOf note, the two studies identify different
Eph receptors as key in CSC mainte-
nance, although some level of crosstalk
likely exists between the Eph receptors
as well as other RTKs central to mainte-
nance of the hierarchy. It would seem
this difference could not be due to differ-
ential representation within the recently
identified GBM subclasses as both
have highest expression in the mesen-
chymal and classical groups (Verhaak
et al., 2010). However, Eph receptors
may be informative within these
subgroups, although that hypothesis
would require further exploration. Impor-
tantly, both groups validate the efficacy
of targeting Eph receptors in preclinical
models.
In conclusion, these two reports are not
simply additions of new CSC markers butrather help reinforce expanding opportu-
nities for integrating features of normal
tissue hierarchies and instructive micro-
environmental cues in tumor develop-
ment and maintenance that can inform
advances in diagnosis and therapy.
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Chromosome rearrangements in B lymphocytes can be initiated by AID-associated double strand breaks
(DSBs), with others arising by unclear mechanisms. A recent study by Barlow and colleagues in Cell reports
on genomic regions, termed early replicating fragile sites, that may explain many AID-independent DSBs and
creates a compelling link between replication stress, transcription, and chromosome rearrangements.Recurrent chromosomal translocations
are common features of many cancers,
especially lymphomas and leukemias.
Most appear to be formed by the joining
of two double strand breaks (DSBs). In
developing B cells, DSBs are introduced
into immunoglobulin loci during V(D)J
recombination and class-switch recombi-
nation (CSR). Both CSR and immunoglob-
ulin somatic hypermutation are initiated
by AID, a single-strand-specific DNA cyti-
dine deaminase targeted to DNA by tran-
scription (Nussenzweig and Nussenz-
weig, 2010). AID-associated DSBs often
generate one of the two breakpoints in
the translocations observed in lymphoid
tumors. This programmed DNA damage
also puts the lymphocyte genome at riskfor rearrangements with bystander loci,
such as the C-MYC locus. Nonetheless,
while many translocations are driven by
off-target AID-induced DSBs, others
result from poorly defined factors that
might include replication errors, oxidative
stress, genotoxic agents, and involve-
ment of chromosome fragile sites.
Common fragile sites (CFSs) have been
recognized for decades as hotspots for
breaks occurring on metaphase chromo-
somes following replication stress (Durkin
and Glover, 2007). Following low doses of
the DNA polymerase inhibitor aphidicolin
(APH), chromosome breaks can be seen
at discrete genomic regions that span
hundreds of kilobases, often in large
genes. CFS instability is dependent onATR signaling and associated with other
DNA damage response factors (Durkin
and Glover, 2007). Le Beau et al. (1998)
and studies that followed showed that
CFSs replicate late in S-phase and some-
times escape to metaphase with incom-
plete replication. For decades, two nonex-
clusive models have existed for CFS
instability. One is that CFSs contain diffi-
cult-to-replicate sequences, leading to
stalled replication forks. The second is
that CFSs contain a paucity of replication
origins, leading to late or incomplete repli-
cation. Support for the former came from
the fact that CFSs are AT-rich and contain
a high number of ‘‘flexibility peaks’’ (Zlo-
torynski et al., 2003) capable of forming
secondary structures, especially whenFebruary 11, 2013 ª2013 Elsevier Inc. 137
